Evidence map›Paper›PMID 33456036›Full record

ArticleInternal medicine (Tokyo, Japan)2021

Peg-IFNα-2a Contributed to HBs Antigen Seroclearance in a Patient with Chronic Hepatitis B Administered Nucleic Acid Analogs: A Three-year Follow-up.

Tomoko Tadokoro, Koji Fujita, Kei Takuma, Mai Nakahara, Kyoko Oura, Shima Mimura, Teppei Sakamoto, Takako Nomura, Joji Tani, Asahiro Morishita and 4 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Clinical Efficacy of PEG-IFNOxidative medicine and cellular longevity · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Tomoko TadokoroDepartment of Gastroenterology and Neurology, Kagawa University School of Medicine/Graduate School of Medicine, Japan.
Koji FujitaDepartment of Gastroenterology and Neurology, Kagawa University School of Medicine/Graduate School of Medicine, Japan.
Kei TakumaDepartment of Gastroenterology and Neurology, Kagawa University School of Medicine/Graduate School of Medicine, Japan.
Mai NakaharaDepartment of Gastroenterology and Neurology, Kagawa University School of Medicine/Graduate School of Medicine, Japan.
Kyoko OuraDepartment of Gastroenterology and Neurology, Kagawa University School of Medicine/Graduate School of Medicine, Japan.
Shima MimuraDepartment of Gastroenterology and Neurology, Kagawa University School of Medicine/Graduate School of Medicine, Japan.
Teppei SakamotoDepartment of Gastroenterology and Neurology, Kagawa University School of Medicine/Graduate School of Medicine, Japan.
Takako NomuraDepartment of Gastroenterology and Neurology, Kagawa University School of Medicine/Graduate School of Medicine, Japan.
Joji TaniDepartment of Gastroenterology and Neurology, Kagawa University School of Medicine/Graduate School of Medicine, Japan.
Asahiro MorishitaDepartment of Gastroenterology and Neurology, Kagawa University School of Medicine/Graduate School of Medicine, Japan.
Hirohito YoneyamaDepartment of Gastroenterology and Neurology, Kagawa University School of Medicine/Graduate School of Medicine, Japan.
Hideki KobaraDepartment of Gastroenterology and Neurology, Kagawa University School of Medicine/Graduate School of Medicine, Japan.
Takashi HimotoDepartment of Gastroenterology and Neurology, Kagawa University School of Medicine/Graduate School of Medicine, Japan.
Tsutomu MasakiDepartment of Gastroenterology and Neurology, Kagawa University School of Medicine/Graduate School of Medicine, Japan.
Kagawa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We treated a 51-year-old Japanese man with chronic hepatitis B (viral load 7.6 LC/mL, genotype C). Hepatitis B virus DNA and HBe antigen were undetectable during the administration of the nucleic acid analogs (NUCs) lamivudine and adefovir, although the concentration of HBs antigen (HBsAg) was 851.2 IU/mL. The HBsAg levels were reduced 150-fold when pegylated-interferon (Peg-IFN) α-2a was administered weekly for 48 weeks and did not increase during the rest period. Therefore, Peg-IFNα-2a was administered twice each week. During this time, HBsAg reached undetectable concentrations, and HBs antibody was detected and continued to be detectable during the three-year follow-up. These unprecedented findings suggest that IFN may contribute to the seroclearance of HBsAg in patients treated with NUCs.

Indexed as

Hepatitis B, ChronicNucleic AcidsAntiviral AgentsDNA, ViralFollow-Up StudiesHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHumansMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsAntiviral AgentsDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensNucleic AcidsPolyethylene GlycolsRecombinant Proteinscase reportschronic hepatitis BHBs antibodyHBs antigeninterferon

Identifiers

PMID33456036
PMCPMC8263180
OpenAlexW3120808341

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.